Origin Enterprises plc (LON:OGN – Get Free Report) shares reached a new 52-week high during mid-day trading on Tuesday following a dividend announcement from the company. The stock traded as high as GBX 3.60 ($0.05) and last traded at GBX 3.52 ($0.05), with a volume of 5500 shares trading hands. The stock had previously closed at GBX 3.45 ($0.05).
The newly announced dividend which will be paid on Friday, February 14th. Shareholders of record on Thursday, January 23rd will be given a €0.14 ($0.15) dividend. The ex-dividend date is Thursday, January 23rd. This represents a yield of 3.96%. This is a boost from Origin Enterprises’s previous dividend of $0.03. Origin Enterprises’s dividend payout ratio is presently 3,953.49%.
Analysts Set New Price Targets
Separately, Shore Capital restated a “buy” rating on shares of Origin Enterprises in a research note on Tuesday.
Origin Enterprises Price Performance
The company’s 50-day moving average price is GBX 3.20 and its 200-day moving average price is GBX 3.17. The company has a quick ratio of 0.69, a current ratio of 1.42 and a debt-to-equity ratio of 94.70. The firm has a market cap of £3.82 million, a price-to-earnings ratio of 8.37 and a beta of 0.72.
Origin Enterprises Company Profile
Origin Enterprises plc provides agronomy services company in Ireland, the United Kingdom, Belgium, Brazil, Poland, Romania, Ukraine, and Latin America. It develops products and services to improve soil fertility, nutrient use efficiency, and crop productivity. The company provides integrated agronomy and on-farm services comprising agronomy advice, services, and inputs directly to arable, fruit, and vegetable growers; and seed, nutrients, crop protection products and digital tools.
Recommended Stories
- Five stocks we like better than Origin Enterprises
- How to Calculate Options Profits
- Biohaven Stock Soars on Drug Trial Results: Time to Jump In?
- Stock Average Calculator
- Is AMD a Legitimate Threat to NVIDIA? What Investors Should Watch
- Upcoming IPO Stock Lockup Period, Explained
- Novo Nordisk’s Setback Won’t Last: A Game-Changing Drug Emerges
Receive News & Ratings for Origin Enterprises Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Origin Enterprises and related companies with MarketBeat.com's FREE daily email newsletter.